Matches in Wikidata for { <http://www.wikidata.org/entity/Q91654263> ?p ?o ?g. }
Showing items 1 to 54 of
54
with 100 items per page.
- Q91654263 description "article scientifique publié en 2019" @default.
- Q91654263 description "artículu científicu espublizáu en febreru de 2019" @default.
- Q91654263 description "scientific article published on 18 February 2019" @default.
- Q91654263 description "wetenschappelijk artikel" @default.
- Q91654263 description "наукова стаття, опублікована в лютому 2019" @default.
- Q91654263 name "The utility of a telemedicine platform to monitor adherence and adverse effects of tyrosine kinase inhibitors" @default.
- Q91654263 name "The utility of a telemedicine platform to monitor adherence and adverse effects of tyrosine kinase inhibitors" @default.
- Q91654263 type Item @default.
- Q91654263 label "The utility of a telemedicine platform to monitor adherence and adverse effects of tyrosine kinase inhibitors" @default.
- Q91654263 label "The utility of a telemedicine platform to monitor adherence and adverse effects of tyrosine kinase inhibitors" @default.
- Q91654263 prefLabel "The utility of a telemedicine platform to monitor adherence and adverse effects of tyrosine kinase inhibitors" @default.
- Q91654263 prefLabel "The utility of a telemedicine platform to monitor adherence and adverse effects of tyrosine kinase inhibitors" @default.
- Q91654263 P1433 Q91654263-42A0642E-A4A4-416C-988D-8981A129C4D4 @default.
- Q91654263 P1476 Q91654263-983EDD66-D6BF-4BF5-B412-20E0A07A3A4A @default.
- Q91654263 P2093 Q91654263-107C7646-0E70-4CAC-892F-33C4D6302C90 @default.
- Q91654263 P2093 Q91654263-302B6993-9536-4E15-8356-755A38A26BB4 @default.
- Q91654263 P2093 Q91654263-36E55856-563C-48B3-B53E-4CE8C5F4B118 @default.
- Q91654263 P2093 Q91654263-3F3929CB-28DE-4AC5-A47C-87135F8ED1DD @default.
- Q91654263 P2093 Q91654263-454D54E6-194B-42D5-8828-4EFF2BC99A86 @default.
- Q91654263 P2093 Q91654263-47841A4A-2C09-4EC8-A796-964A0EC2C629 @default.
- Q91654263 P2093 Q91654263-884D9FD4-8492-4D25-B856-9FE7BA1BE1CD @default.
- Q91654263 P2093 Q91654263-A8267E15-46BD-4EE6-BF3D-366049EFD14C @default.
- Q91654263 P2093 Q91654263-EC0CFA98-8575-4263-8368-3D4DFE2B5F26 @default.
- Q91654263 P304 Q91654263-DA97CF94-DF2F-4A2C-8FFE-18F348BF1F1B @default.
- Q91654263 P31 Q91654263-196EDA74-3A63-4EF0-B65D-606A4BDC3D1D @default.
- Q91654263 P356 Q91654263-11196A36-3385-4C3F-985E-035369B19990 @default.
- Q91654263 P433 Q91654263-C1FC6C4B-4B12-4FA6-916E-4370AFE79DAF @default.
- Q91654263 P478 Q91654263-ACEB338D-250B-4C53-A0F4-0C817A627F63 @default.
- Q91654263 P50 Q91654263-EC9C955C-DE85-464B-8EC3-AE131AFF8DB1 @default.
- Q91654263 P577 Q91654263-3FD8B623-B2AC-41A8-88A6-4482F8F6309D @default.
- Q91654263 P698 Q91654263-9D3F6132-913D-438E-9A85-57A84B5F58C1 @default.
- Q91654263 P921 Q91654263-B25BC100-D96F-487C-B692-420DBA9E9FB0 @default.
- Q91654263 P356 10428194.2018.1551540 @default.
- Q91654263 P698 30773105 @default.
- Q91654263 P1433 Q6534493 @default.
- Q91654263 P1476 "The utility of a telemedicine platform to monitor adherence and adverse effects of tyrosine kinase inhibitors" @default.
- Q91654263 P2093 "Anastasia Ivanova" @default.
- Q91654263 P2093 "Anderson Black" @default.
- Q91654263 P2093 "Anureet C Copeland" @default.
- Q91654263 P2093 "Benyam Muluneh" @default.
- Q91654263 P2093 "James G Xenakis" @default.
- Q91654263 P2093 "Matthew C Foster" @default.
- Q91654263 P2093 "Monique Clayton" @default.
- Q91654263 P2093 "Olga Frankfurt" @default.
- Q91654263 P2093 "Robert S Wehbie" @default.
- Q91654263 P304 "1842-1844" @default.
- Q91654263 P31 Q13442814 @default.
- Q91654263 P356 "10.1080/10428194.2018.1551540" @default.
- Q91654263 P433 "7" @default.
- Q91654263 P478 "60" @default.
- Q91654263 P50 Q91654260 @default.
- Q91654263 P577 "2019-02-18T00:00:00Z" @default.
- Q91654263 P698 "30773105" @default.
- Q91654263 P921 Q46994 @default.